Bandaram pharma packtech Limited has filed its quarterly compliance certificate with BSE Limited, fulfilling regulatory requirements under SEBI (Depositories & Participants) Regulations, 2018. The submission, dated 11.04.2026, covers the quarter ended 31.03.2026 and demonstrates the company's adherence to dematerialisation compliance standards.

Regulatory Compliance Filing

The compliance certificate was submitted under Regulation 74(5) of SEBI (Depositories & Participants) Regulations, 2018. Chairman and Managing Director Deepak Bandaram signed the submission letter, which was addressed to BSE Limited at P. J. Towers, Dalal Street, Mumbai.

Certificate Confirmation by RTA

Cameo Corporate Services Limited, serving as the company's Registrar and Transfer Agent, issued the compliance certificate on 03rd April, 2026. The RTA confirmed that all securities received from depository participants for dematerialisation during Q4FY26 were properly processed and confirmed to the depositories.

Dematerialisation Process Compliance

The certificate validates several key compliance aspects of the dematerialisation process. Cameo Corporate Services confirmed that securities received during the quarter were appropriately accepted or rejected, and that these securities have been listed on stock exchanges where the company's earlier issued securities are already listed.

Process Verification Standards

The RTA confirmed that security certificates received for dematerialisation were mutilated and cancelled after due verification by the depository participant. Additionally, the names of the depositories have been substituted in the register of members as registered owners within the stipulated time limits under the captioned regulations.

This quarterly compliance filing demonstrates Bandaram Pharma Packtech Limited's commitment to maintaining proper regulatory standards and ensuring transparent dematerialisation processes for its shareholders.

Bandaram Pharma Packtech Limited has submitted its notice for the 1st Extraordinary General Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, scheduled for April 27, 2026.

EGM Submission and Compliance

The company formally submitted the EGM notice to BSE Limited on April 3, 2026, signed by Chairman and Managing Director Deepak Bandaram (DIN: 07074102). The meeting will be conducted through Video Conference/Other Audio-Visual Means (VC/OAVM) facility at 11:00 a.m.

Key Agenda Items

The EGM will address three significant resolutions requiring shareholder approval:

Director Appointment

Appointment of Mr. Eswar Reddy Putturu (DIN: 11510880) as Independent Director for a five-year term from January 30, 2026, to January 29, 2031. The MBA professional with expertise in finance and marketing holds 24,371 equity shares (0.20%) in the company.

Material Related Party Transactions

Two separate proposals for material RPTs with subsidiary VSR Paper and Packaging Limited:

Financial Context and Rationale

The proposed transactions represent 135.26% of Bandaram Pharma Packtech's annual consolidated turnover of ₹36.96 crores. The company holds 51.08% equity stake in VSR Paper and Packaging Limited, which reported turnover of ₹35.37 crores and profit after tax of ₹0.85 crores.

Corporate Governance Framework

The transactions require shareholder approval as they exceed the 10% materiality threshold of ₹3.696 crores based on annual consolidated turnover. The Audit Committee and Board have approved these transactions, emphasizing the strategic importance of VSR Paper as a key vendor for raw materials and finished goods distribution.

The company has appointed Vivek Surana & Associates as scrutinizer for the e-voting process, with remote e-voting available from April 24-26, 2026. Related parties will abstain from voting on the resolutions as per regulatory requirements.